Navigation Links
Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension
Date:10/23/2007

stage PAH patients as a monotherapy.

About Tracleer(R) in Pulmonary Arterial Hypertension (PAH)

Tracleer(R) (bosentan), the first oral dual endothelin receptor antagonist, is approved for the treatment of pulmonary arterial hypertension (PAH) and made available by Actelion Ltd. subsidiaries in the United States, the European Union, Japan, Australia, Canada, Switzerland and other markets worldwide.

Tracleer requires attention to two significant safety concerns: potential for serious liver injury (including rare cases of liver failure and unexplained hepatic cirrhosis in a setting of close monitoring) and high potential for major birth defects. Liver monitoring of all patients is essential prior to initiation of treatment and monthly thereafter. Pregnancy must be excluded and prevented by two forms of birth control; monthly pregnancy tests should be obtained. Because of these risks, Tracleer is only supplied through a controlled distribution system.

About Actelion Pharmaceuticals

Actelion Pharmaceuticals has pioneered research and development in the pulmonary arterial hypertension (PAH) disease area. More than 40,000 PAH patients have been prescribed Actelion's product Tracleer(R) (bosentan), an orally available dual endothelin receptor antagonist for patients with World Health Organization (WHO) Class III or IV PAH in the U.S., and Class III PAH in Europe. Tracleer was approved in 2001 as the first oral treatment for PAH, and is currently approved in the U.S., the European Union, and other markets worldwide. In January 2007, Actelion acquired CoTherix, Inc., whose product Ventavis(R) (iloprost) Inhalation Solution is approved and marketed in the United States for the treatment of patients with WHO Class III or IV PAH.


'/>"/>
SOURCE Actelion Pharmaceuticals US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... LEIPZIG, Germany , Sept. 17, 2014 ... entered into an exclusive technology development partnership with ... agents to image CD4+ positive immune T cells. ... capability to precisely diagnose and determine therapeutic options ... The ability to image CD4+ T-cells will also ...
(Date:9/17/2014)... , Sept. 17, 2014   GS1 ... how to implement GS1 Standards to support the ... enhance patient safety and security in the pharmaceutical ... GS1 Standards to U.S. Pharmaceutical Supply Chain Business ... Act , was developed in collaboration with ...
(Date:9/17/2014)... Calif. , Sept. 17, 2014 ... announced that it has earned a $4 million ... AKAO ) associated with the initiation of a ... serious multi-drug resistant (MDR), gram-negative bacterial infections.  The ... study to evaluate the efficacy and safety of ...
Breaking Medicine Technology:ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3
(Date:9/18/2014)... Atlanta, GA (PRWEB) September 18, 2014 ... Counselor, recognizes that 1- sometimes, inner beauty has to ... strengths have to be acknowledged in order to be ... , Healing Hearts shows the world how to do ... Counseling and Life Coaching using the Healing Hearts system, ...
(Date:9/18/2014)... Mateo, CA (PRWEB) September 18, 2014 ... archiving solutions, from active, to medium, and even long ... of content for any length of time. This includes ... of machine-produced data. When used together, Nautilus and ASG-Digital ... managing archive content. , "storageFOUNDRY is pleased to ...
(Date:9/17/2014)... (PRWEB) September 18, 2014 Recently, UWDress.com, ... dresses and women’s special occasion outfits, has released its ... In addition, the firm has launched a big sale ... are now available at deeply discounted rates, from 15 ... that the company insists on using comfortable to wear ...
(Date:9/17/2014)... Charlotte, NC (PRWEB) September 18, 2014 ... , U.S. emergency departments treat an estimated 173,285 sports- ... and adolescents every year. Soon, a blood test may ... concussion is and how long recovery will take. ... reported that they have found a way to ...
(Date:9/17/2014)... According to an August 5, ... “Adverse Events Associated with Use of Enhancement Medical's ... use of Expression, a hyaluronic acid product, for ... including discoloration, lumps, bruising, nodules, and swelling. ... cosmetic use include Restylane , Juvéderm, Perlane, ...
Breaking Medicine News(10 mins):Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 2Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 3Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 2Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 3Health News:2014 Empire Waist Evening Dress Collection Now Unveiled At UWDress.com 2Health News:Breakthrough blood test will improve concussion diagnoses, treatment 2Health News:Breakthrough blood test will improve concussion diagnoses, treatment 3Health News:Simon Ourian, Kim Kardashian's Cosmetic Surgeon, Warns About Illegal Use of Expression as a Dermal Filler 2
... effort to uncover the medium- and large-scale genetic differences between ... a wide range of diseases, according to a paper by ... published in the May 10, 2007, Nature. The undertaking will ... says amount to as much as five to ten percent ...
... study examines the use of tissue-engineered scaffolding made of cartilage ... replace defective cartilage tissue. ,Cartilage cells are ... the body, where new cartilage tissue is grown along the ... ,The procedure was extremely successful in tested mice as ...
... immune systems of humans and opossums, the famous Australian ... breakthroughs in the understanding and treatment of facial tumours ... in the Australian island state of Tasmania. ... of genetic information of the South American opossum, the ...
... Breakthrough research has offered a clue as to why oral ... in persons not regarded as primary-risk candidates . American scientists ... passes on the human papillomavirus or HPV between partners and ... does not smoke, drink or use any substance known to ...
... study reveals that almost two-thirds of US children ... but very few of them experience post-traumatic stress ... resilience in children, but it also suggests that the ... said William Copeland of Duke University Medical Center, whose ...
... cervical cancer is nearly 100 percent effective against the two ... cases of cervical cancer. Results of a nationwide study of ... of the New England Journal of Medicine. ,But ... three shots of a new HPV vaccine marketed by Merck ...
Cached Medicine News:Health News:Cataloging the Structural Variations in Human Genetics 2Health News:Cataloging the Structural Variations in Human Genetics 3Health News:Treatment of Premature Babies, Opossums Could Help 2Health News:Swallowing The Bitter Pill-Oral Sex Linked To Oral Cancer 2Health News:Two-thirds of US Children Experience Trauma, but Recover Fast 2Health News:Study Shows Continued Success for New HPV Vaccine Against Virus 2
... The Minifold I system consists of four basic ... plenum, and metal clamping plate (see diagram). The ... for producing spots, dots, or slots (see below). ... purchased as an accessory plate in conjunction with ...
... Minifold I system consists of four basic components: ... and metal clamping plate (see diagram). The sample ... producing spots, dots, or slots (see below). All ... as an accessory plate in conjunction with a ...
... SF (slot format) microfiltration units provide a ... acid in solution onto nitrocellulose or Zeta-Probe ... by using interchangeable templates to form the ... Bio-Dot SF apparatus. Each is available as ...
... and Bio-Dot SF (slot format) microfiltration units ... or nucleic acid in solution onto nitrocellulose ... be accommodated by using interchangeable templates to ... slot format Bio-Dot SF apparatus. Each is ...
Medicine Products: